A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

An Open Label Sequential Dose Response Observational Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

Status

Terminated

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00347646

Enrollment

Registered

2006-07-04

Start date

2006-09-30

Completion date

2007-06-30

Last updated

2019-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitreoretinal Traction Syndrome

Brief summary

Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.

Interventions

DRUGPlasmin

27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who are in need of a vitrectomy.

Exclusion criteria

* A PVD in the study eye as assessed by the investigator using ophthalmic and alternative examination techniques. * A history of vitrectomy in the study eye. * A media opacity that precludes quality examination of the vitreous and fundus in the study eye.

Design outcomes

Primary

Measure	Time frame	Description
Presence of a Posterior Vitreous Detachment (PVD)	14 days	Presence of posterior vitreous detachment evaluated durning virectomy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026